Rivaroxabana após hospitalização por covid-19: estudo MICHELLE

O ensaio clínico aberto e randomizado mostra melhores resultados com uma dose baixa de anticoagulante oral de ação direta em pacientes com alto risco de TEV e baixo risco de sangramento.

Fonte: Rivaroxabana após hospitalização por covid-19: estudo MICHELLE

Aqui o link para a publicação do Lancet

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02392-8/fulltext

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients | NEJM

Original Article from The New England Journal of Medicine — Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Fonte: Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients | NEJM

 Resultados modestos. Mas é um passo adiante

SARS-CoV-2 vaccine protection and deaths among US veterans during 2021


Fonte: SARS-CoV-2 vaccine protection and deaths among US veterans during 2021

O gráfico fala por si. Não era só a coronavac afinal…

Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis | NEJM

Original Article from The New England Journal of Medicine — Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis

Fonte: Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis | NEJM

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile | NEJM


Original Article from The New England Journal of Medicine — Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

Fonte: Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile | NEJM

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia | NEJM

Original Article from The New England Journal of Medicine — Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

Fonte: Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia | NEJM

 

A integra do artigo da NEJM do post anterior

Another JAK Inhibitor Shows Mortality Benefit in COVID-19 | MedPage Today

Tofacitinib cut incidence of severe outcomes in a population where most received steroids

Fonte: Another JAK Inhibitor Shows Mortality Benefit in COVID-19 | MedPage Today

Neurologic Disease after Yellow Fever Vaccination, São Paulo, Brazil, 2017–2018 – Volume 27, Number 6—June 2021 – Emerging Infectious Diseases journal – CDC

Disease should be diagnosed by using the Brighton Collaboration case definitions and cerebrospinal fluid IgM reactivity.

Fonte: Neurologic Disease after Yellow Fever Vaccination, São Paulo, Brazil, 2017–2018 – Volume 27, Number 6—June 2021 – Emerging Infectious Diseases journal – CDC

Publicação com a participação do nosso contemporâneo de residência, Dr. Augusto Penalva

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination | NEJM


Original Article from The New England Journal of Medicine — Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Fonte: Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination | NEJM

Síndrome pós-aguda por Covid-19


https://www.nature.com/articles/s41591-021-01283-z.pdf?fbclid=IwAR3RjmPqJ_E4nN23TBb5phDlASXwHE4EbpwuMEKob3mACxcGHgyt5Yy-otU

Artigo da nature.
Síndrome pós-aguda COVID-19
Uma revisão abrangente da literatura atual sobre COVID-19 pós-aguda, a sua patofisiologia e as suas sequelas específicas para os órgãos.